keyword
https://read.qxmd.com/read/38529422/advancements-in-mitraclip-intervention-for-mitral-regurgitation-a-comprehensive-review-and-comparative-analysis-of-clinical-trials
#1
REVIEW
Shitij Shrivastava, Shashwat Shrivastava, Sai Vishnu Vardhan Allu, Patrik Schmidt, Moiud Mohyeldin, Abeer Qasim
This comprehensive review explores the evolution and clinical impact of MitraClip intervention in the management of mitral regurgitation. Mitral regurgitation results from dysfunction in the mitral valve (MV) apparatus. The MitraClip Clip Delivery System was approved by the Food and Drug Administration (FDA) in 2013. The discussion delves into the procedural foundation of MitraClip intervention, primarily based on Alfieri's technique of edge-to-edge leaflet approximation. As highlighted by key clinical trials, including Endovascular Valve Edge-to-Edge Repair (EVEREST) II Trial, Cardiovascular Outcomes Assessment of the MitraClip Percutaneous Therapy for Heart Failure Patients with Functional Mitral Regurgitation (COAPT) Trial, and Percutaneous Repair with the MitraClip Device for Severe Functional/Secondary Mitral Regurgitation (MITRA-FR) trial, the efficacy and safety of MitraClip were evaluated in comparison to surgical interventions and guideline-directed medical therapy...
February 2024: Curēus
https://read.qxmd.com/read/38527130/scrutinizing-the-role-of-venoarterial-extracorporeal-membrane-oxygenation-has-clinical-practice-outpaced-the-evidence
#2
REVIEW
Enzo Lüsebrink, Leonhard Binzenhöfer, Daniel Hering, Laura Villegas Sierra, Benedikt Schrage, Clemens Scherer, Walter S Speidl, Aitor Uribarri, Manel Sabate, Marko Noc, Elena Sandoval, Andrejs Erglis, Federico Pappalardo, Frederic De Roeck, Guido Tavazzi, Jordi Riera, Roberto Roncon-Albuquerque, Benjamin Meder, Peter Luedike, Tienush Rassaf, Jörg Hausleiter, Christian Hagl, Sebastian Zimmer, Dirk Westermann, Alain Combes, Uwe Zeymer, Steffen Massberg, Andreas Schäfer, Martin Orban, Holger Thiele
The use of venoarterial extracorporeal membrane oxygenation (VA-ECMO) for temporary mechanical circulatory support in various clinical scenarios has been increasing consistently, despite the lack of sufficient evidence regarding its benefit and safety from adequately powered randomized controlled trials. Although the ARREST trial (Advanced Reperfusion Strategies for Patients with Out-of-Hospital Cardiac Arrest and Refractory Ventricular Fibrillation) and a secondary analysis of the PRAGUE OHCA trial (Prague Out-of-Hospital Cardiac Arrest) provided some evidence in favor of VA-ECMO in the setting of out-of-hospital cardiac arrest, the INCEPTION trial (Early Initiation of Extracorporeal Life Support in Refractory Out-of-Hospital Cardiac Arrest) has not found a relevant improvement of short-term mortality with extracorporeal cardiopulmonary resuscitation...
March 26, 2024: Circulation
https://read.qxmd.com/read/38520248/use-of-cardiac-contractility-modulation-combined-with-left-bundle-branch-pacing-crt-p-in-a-female-with-a-22-year-history-of-non-ischemic-dilated-cardiomyopathy-a-case-report
#3
Lili Fang, Yuxiao Ma, Yueming Wu, Yan Ge, Xianming Liang, Rong Tang
Cardiac contractility modulation (CCM) is a novel device-based therapy used to treat patients with heart failure with reduced ejection fraction (HFrEF). In both randomized clinical trials and real-life studies, CCM has been shown to improve exercise tolerance and quality of life, reverse left ventricular remodeling, and reduce hospitalization in patients with HFrEF. In this case report, we describe for the first time the use of CCM combined with left bundle branch pacing (LBBP) cardiac resynchronization therapy pacemaker (CRT-P) implantation therapy in a female with a 22-year history of non-ischemic dilated cardiomyopathy...
March 2024: Echocardiography
https://read.qxmd.com/read/38517852/patient-decision-making-in-left-ventricular-assist-devices-for-destination-therapy
#4
JOURNAL ARTICLE
Megan L Morrison
BACKGROUND: Heart failure is a common life-limiting disease. A destination therapy for people who will not have a heart transplant is a left ventricular assist device. AIMS: To discover how patients who have a left ventricular assist device for destination therapy make decisions about their healthcare after implantation of the device. METHODS: A descriptive qualitative design with semi-structured, in-depth interviews with 11 participants who are living with a left ventricular assist device for destination therapy...
March 2, 2024: International Journal of Palliative Nursing
https://read.qxmd.com/read/38517620/a-computational-investigation-of-the-effects-of-temporal-synchronization-of-left-ventricular-assist-device-speed-modulation-with-the-cardiac-cycle-on-intraventricular-hemodynamics
#5
JOURNAL ARTICLE
Angela Straccia, Fanette Chassagne, Michael C Barbour, Jennifer Beckman, Song Li, Claudius Mahr, Alberto Aliseda
Patients with advanced heart failure are implanted with a left ventricular assist device (LVAD) as a bridge-to-transplantation or destination therapy. Despite advances in pump design, the risk of stroke remains high. LVAD implantation significantly alters intraventricular hemodynamics, where regions of stagnation or elevated shear stresses promote thrombus formation. Third generation pumps incorporate a pulsatility mode that modulates rotational speed of the pump to enhance in-pump washout. We investigated how the timing of the pulsatility mode with the cardiac cycle affects intraventricular hemodynamic factors linked to thrombus formation...
March 22, 2024: Annals of Biomedical Engineering
https://read.qxmd.com/read/38516693/endovascular-transplantation-of-mrna-enhanced-mesenchymal-stromal-cells-results-in-superior-therapeutic-protein-expression-in-swine-heart
#6
JOURNAL ARTICLE
Jonathan Al-Saadi, Mathias Waldén, Mikael Sandell, Jesper Sohlmér, Rikard Grankvist, Ida Friberger, Agneta Andersson, Mattias Carlsten, Kenneth Chien, Johan Lundberg, Nevin Witman, Staffan Holmin
Heart failure has a poor prognosis and no curative treatment exists. Clinical trials are investigating gene- and cell-based therapies to improve cardiac function. The safe and efficient delivery of these therapies to solid organs is challenging. Herein, we demonstrate the feasibility of using an endovascular intramyocardial delivery approach to safely administer mRNA drug products and perform cell transplantation procedures in swine. Using a trans -vessel wall (TW) device, we delivered chemically modified mRNAs (modRNA) and mRNA-enhanced mesenchymal stromal cells expressing vascular endothelial growth factor A (VEGF-A) directly to the heart...
June 13, 2024: Molecular Therapy. Methods & Clinical Development
https://read.qxmd.com/read/38500751/advanced-hemodynamics-for-prognostication-in-heart-failure-the-pursuit-of-the-patient-specific-tipping-point
#7
JOURNAL ARTICLE
Jonathan Grinstein
BACKGROUND: Objective tools to define the optimal time for referral for advanced therapies and to help guide escalation and de-escalation of support can improve management decisions and outcomes for patients with advanced heart failure. The current parameters have variable prognostic potential depending on the patient population being studied and often have arbitrary thresholds. METHODS: Here, a mathematical and physiological framework to define the patient-specific tipping point of myocardial energetics is defined...
2024: Frontiers in Cardiovascular Medicine
https://read.qxmd.com/read/38500489/inadvertent-septal-perforation-during-conduction-system-pacing-device-implant-a-case-report
#8
Jurgen Shtembari, Dhan Bahadur Shrestha, Roderick Tung, Gaurav A Upadhyay
BACKGROUND: There has been recent growing interest in the use of conduction system pacing (CSP) for both bradycardia and heart failure indications. There remains a paucity of data, however, regarding complications related to the intraventricular septum associated with CSP implant and the management of these events. CASE SUMMARY: We present a case of a patient with non-ischemic dilated cardiomyopathy presenting for cardiac resynchronization therapy in whom left bundle branch area pacing was complicated with interventricular septal perforation and managed intra-procedurally with repositioning of the lead to provide His bundle pacing (HBP) for QRS correction of underlying left bundle branch block...
March 2024: European Heart Journal. Case Reports
https://read.qxmd.com/read/38488713/preliminary-report-of-extracorporeal-blood-purification-therapy-in-patients-receiving-lvad-cytosorb-or-jafron-ha330
#9
RANDOMIZED CONTROLLED TRIAL
Zhuldyz Nurmykhametova, Timur Lesbekov, Rymbay Kaliyev, Bolat Bekishev, Nilufar Jabayeva, Svetlana Novikova, Linar Faizov, Ivan Vakhrushev, Yuriy Pya
BACKGROUND: Left ventricular assist device (LVAD) candidates are at increased risk of immune dysregulation and infectious complications. To attenuate the elevated proinflammatory cytokine levels and associated adverse clinical outcomes, it has been postulated that extracorporeal blood purification could improve the overall survival rate and morbidity of patients undergoing LVAD implantation. METHODS: We retrospectively reviewed prospectively collected data of 15 patients who underwent LVAD implantation at our center between January 2021 and March 2022...
March 2024: Journal of Extra-corporeal Technology
https://read.qxmd.com/read/38470133/-pseudomonas-aeruginosa-ventricular-assist-device-infections-findings-from-ineffective-phage-therapies-in-five-cases
#10
JOURNAL ARTICLE
Saima Aslam, Dwayne Roach, Mikeljon P Nikolich, Biswajit Biswas, Robert T Schooley, Kimberley A Lilly-Bishop, Gregory K Rice, Regina Z Cer, Theron Hamilton, Matthew Henry, Tiffany Luong, Ann-Charlott Salabarria, Laura Sisk-Hackworth, Andrey A Filippov, Francois Lebreton, Lindsey Hall, Ran Nir-Paz, Hadil Onallah, Gilat Livni, Eran Shostak, Anat Wieder-Finesod, Dafna Yahav, Ortal Yerushalmy, Sivan Alkalay-Oren, Ron Braunstein, Leron Khalifa, Amit Rimon, Daniel Gelman, Ronen Hazan
Left ventricular assist devices (LVAD) are increasingly used for management of heart failure; infection remains a frequent complication. Phage therapy has been successful in a variety of antibiotic refractory infections and is of interest in treating LVAD infections. We performed a retrospective review of four patients that underwent five separate courses of intravenous (IV) phage therapy with concomitant antibiotic for treatment of endovascular Pseudomonas aeruginosa LVAD infection. We assessed phage susceptibility, bacterial strain sequencing, serum neutralization, biofilm activity, and shelf-life of phage preparations...
March 12, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38462933/the-role-of-palliative-care-for-patients-with-left-ventricular-assist-devices-a-narrative-review
#11
JOURNAL ARTICLE
Badr Abdullah, Richa Gupta, Kelley M Anderson, Keki Balsara, Farooq H Sheikh, Hunter Groninger, Anirudh Rao
BACKGROUND AND OBJECTIVE: Left ventricular assist devices (LVADs) have revolutionized the care of patients with advanced heart failure (HF). Compared to guideline-directed medical and device therapies, LVAD technology improves quality of life and reduces mortality. Palliative care specialists have an important role to play in the pre-LVAD evaluation phase, in the post-operative longitudinal care phase, and at the endof-life in patients with LVADs. The objective of this narrative review is to describe the evidence regarding the role of palliative care for patients with LVAD across the care continuum: pre-implantation, postimplantation, and at the end-of-life...
February 27, 2024: Annals of Palliative Medicine
https://read.qxmd.com/read/38462324/surgical-considerations-in-adult-congenital-heart-disease-heart-failure
#12
REVIEW
William H Marshall V, Patrick McConnell
Surgical intervention is often used in the management of heart failure in patients with adult congenital heart disease. This review addresses anatomic variations and complications due to prior surgical interventions, including sternal reentry, collateral vessels, and the neo-aortic root after the Damus-Kaye-Stansel procedure. Surgical considerations for systemic atrioventricular valvular surgery, Fontan revision, and advanced heart failure therapies including ventricular assist devices, heart transplant, and combined heart-liver transplant are discussed, with a focus on unique patient populations including those with systemic right ventricles and those with Fontan circulation...
April 2024: Heart Failure Clinics
https://read.qxmd.com/read/38462322/arrhythmias-in-adult-congenital-heart-disease-heart-failure
#13
REVIEW
Anudeep K Dodeja, Shailendra Upadhyay
Heart failure and arrhythmias represent 2 major causes of mortality and morbidity in adults with congenital heart disease. Arrhythmias and heart failure are interdependent, and one may exacerbate the other. Treatment of one also has a positive impact on the other. Management approaches need to be multifaceted, including pharmacotherapy, optimization of hemodynamic status with catheter-based or surgical interventions, and specific management of arrhythmia with device or catheter ablation therapy.
April 2024: Heart Failure Clinics
https://read.qxmd.com/read/38462320/special-considerations-for-mechanical-circulatory-support-or-device-therapy-in-adult-congenital-heart-disease-heart-failure
#14
REVIEW
Rafael Alonso-Gonzalez, Guillermo Agorrody
Heart failure has become the leading cause of mortality in adult congenital heart disease (ACHD) patients after the fifth decade of life. There is scanty evidence supporting the use of guideline-directed medical therapy in ACHD, especially in systemic right ventricle or single ventricle physiology. In complex patients, diagnosing heart failure and timely referral for advanced therapies are challenging. Mechanical circulatory support has been significantly developed over the past decade and has recently emerged as a feasible therapeutic option for these patients...
April 2024: Heart Failure Clinics
https://read.qxmd.com/read/38459252/sex-related-similarities-and-differences-in-responses-to-heart-failure-therapies
#15
REVIEW
Janice Y Chyou, Hailun Qin, Javed Butler, Adriaan A Voors, Carolyn S P Lam
Although sex-related differences in the epidemiology, risk factors, clinical characteristics and outcomes of heart failure are well known, investigations in the past decade have shed light on an often overlooked aspect of heart failure: the influence of sex on treatment response. Sex-related differences in anatomy, physiology, pharmacokinetics, pharmacodynamics and psychosocial factors might influence the response to pharmacological agents, device therapy and cardiac rehabilitation in patients with heart failure...
March 8, 2024: Nature Reviews. Cardiology
https://read.qxmd.com/read/38456998/cardiac-ecmo-changing-role-in-times-of-impella-and-ventricular-assist-devices
#16
REVIEW
Holger Thiele
Mortality in infarct-related as well as heart failure-associated cardiogenic shock remains high, reaching 40-50% depending on the etiology and severity of cardiogenic shock. Percutaneous active mechanical circulatory support devices including veno-arterial extracorporeal membrane oxygenation (VA-ECMO) and microaxial left ventricular mechanical circulatory support devices are rapidly evolving in their use. However, evidence of VA-ECMO therapy has only recently emerged and showed no benefit for mortality, with an associated higher complication rate...
March 8, 2024: Medizinische Klinik, Intensivmedizin und Notfallmedizin
https://read.qxmd.com/read/38456308/impact-of-advanced-therapy-centers-on-characteristics-and-outcomes-of-heart-failure-admissions
#17
JOURNAL ARTICLE
Daniel Y Lu, Jaya Kanduri, Ilhwan Yeo, Parag Goyal, Udhay Krishnan, Evelyn M Horn, Maria G Karas, Irina Sobol, David T Majure, Yoshifumi Naka, Robert M Minutello, Jim W Cheung, Nir Uriel, Luke K Kim
BACKGROUND: Although much attention has been paid to admission and transfer patterns for cardiogenic shock, contemporary data are lacking on decompensated heart failure (HF) admissions and transfers and the impact of advanced therapy centers (ATCs) on outcomes. METHODS: HF hospitalizations were obtained from the Nationwide Readmissions Database 2016 to 2019. Centers performing at least 1 heart transplant or left ventricular assist device were classified as ATCs...
March 8, 2024: Circulation. Heart Failure
https://read.qxmd.com/read/38452999/wearable-sensors-to-monitor-physical-activity-in-heart-failure-clinical-trials-state-of-the-art-review
#18
REVIEW
Ruben Buendia, Martin Karpefors, Folke Folkvaljon, Robert Hunter, Henrik Sillen, Long Luu, Kieran Docherty, Martin R Cowie
BACKGROUND: Estimation of the effect that a drug or other intervention has on patient symptoms and functions is crucial in heart failure trials. Traditional symptoms and functions clinical outcome assessments have important limitations. Actigraphy may help to overcome these limitations due to its objective nature and the potential for continuous recording of data. However, actigraphy is not currently accepted as clinically relevant by key stakeholders. METHODS AND RESULTS: In this This State-of-the-Art paper, the key aspects to consider when implementing actigraphy in heart failure trials are discussed...
March 5, 2024: Journal of Cardiac Failure
https://read.qxmd.com/read/38451550/withdrawal-of-left-ventricular-assist-device-in-dementia-a-case-report
#19
JOURNAL ARTICLE
Nicholas E Morley, Cristina M Ramirez-Urquiola, Shunichi Nakagawa
Left ventricular assistance devices (LVADs) are one type of life support with the unique quality of allowing recipients to live outside the hospital. This case report explores the decision by a patient and their family to withdraw LVAD therapy in the setting of dementia and consultant team recommendations at odds with one another due to the patient's simultaneous alertness and lack of decisional capacity. It then discusses the guiding principles that led to the withdrawal of LVAD therapy and lessons drawn from the experience by the care team...
March 6, 2024: Journal of Palliative Medicine
https://read.qxmd.com/read/38449780/potential-role-of-cardiopulmonary-exercise-testing-in-evaluating-functional-improvement-after-transcatheter-edge-to-edge-tricuspid-valve-repair-a-case-report
#20
Luca Cumitini, Ailia Giubertoni, Marco Giovanni Mennuni, Anna Degiovanni, Giuseppe Patti
BACKGROUND: Tricuspid regurgitation (TR) is common and severe or greater TR is linked to poor prognosis. Treatment of TR with transcatheter edge-to-edge repair has emerged as a safe and potentially effective therapy in these patients. However, the impact of transcatheter tricuspid repair on functional capacity remains to be elucidated. CASE SUMMARY: We describe the case of a 77-year-old woman complaining of heart failure symptoms, undergoing transcatheter edge-to-edge valve repair for severe TR with the PASCAL Ace® device...
March 2024: European Heart Journal. Case Reports
keyword
keyword
71479
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.